5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hypocortisolism O
: O
Decreases O
in O
circulating O
levels O
of O
cortisol O
may O
occur O
resulting O
in O
biochemical O
and/or O
clinical O
hypocortisolism O
. O

SIGNIFOR O
dose O
reduction O
or O
interruption O
and/or O
adding O
a O
low-dose O
short-term O
glucocorticoid O
may O
be O
necessary O
( O
5.1 O
) O
* O
Hyperglycemia O
and O
Diabetes O
( O
occurs O
with O
initiation O
) O
: O
Intensive O
glucose O
monitoring O
is O
recommended O
and O
may O
require O
initiation O
or O
adjustment O
of O
anti-diabetic O
treatment O
per O
standard O
of O
care O
( O
5.2 O
) O
* O
Bradycardia O
and O
QT O
Prolongation O
: O
Use O
with O
caution O
in O
at-risk O
patients O
; O
ECG O
testing O
prior O
to O
dosing O
and O
on O
treatment O
( O
5.3 O
, O
7.1 O
) O
* O
Liver O
Test O
Elevations O
: O
Evaluate O
liver O
tests O
prior O
to O
and O
during O
treatment O
( O
5.4 O
) O
* O
Cholelithiasis O
: O
Perform O
gallbladder O
ultrasounds O
before O
starting O
treatment O
and O
at O
6-month O
intervals O
( O
5.5 O
) O
5.1 O
Hypocortisolism O
Treatment O
with O
SIGNIFOR O
leads O
to O
suppression B-Not_AE_Candidate
of I-Not_AE_Candidate
adrenocorticotropic I-Not_AE_Candidate
hormone I-Not_AE_Candidate
( I-Not_AE_Candidate
ACTH I-Not_AE_Candidate
) I-Not_AE_Candidate
secretion I-Not_AE_Candidate
in I-Not_AE_Candidate
Cushing I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Suppression B-Not_AE_Candidate
of I-Not_AE_Candidate
ACTH I-Not_AE_Candidate
may O
lead O
to O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
circulating I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
of I-OSE_Labeled_AE
cortisol I-OSE_Labeled_AE
and O
potentially O
hypocortisolism B-OSE_Labeled_AE
. O

Monitor O
and O
instruct O
patients O
on O
the O
signs O
and O
symptoms O
associated O
with O
hypocortisolism B-NonOSE_AE
( O
e.g. O
, O
weakness B-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
anorexia B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
hyponatremia B-NonOSE_AE
or O
hypoglycemia B-NonOSE_AE
) O
. O

If O
hypocortisolism B-NonOSE_AE
occurs O
, O
consider O
temporary O
dose O
reduction O
or O
interruption O
of O
treatment O
with O
SIGNIFOR O
, O
as O
well O
as O
temporary O
, O
exogenous O
glucocorticoid O
replacement O
therapy O
. O

5.2 O
Hyperglycemia B-OSE_Labeled_AE
and O
Diabetes O
Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
have O
been O
seen O
in O
healthy O
volunteers O
and O
patients O
treated O
with O
SIGNIFOR O
. O

In O
the O
Phase O
III O
trial O
, O
the O
development O
of O
pre B-OSE_Labeled_AE
- I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
and O
diabetes B-OSE_Labeled_AE
was O
observed O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

In O
this O
trial O
, O
nearly O
all O
patients-including O
those O
with O
normal O
glucose O
status O
at O
baseline O
, O
pre B-Not_AE_Candidate
- I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
, O
and O
diabetes B-Not_AE_Candidate
-developed O
worsening B-OSE_Labeled_AE
glycemia I-OSE_Labeled_AE
in O
the O
first O
two O
weeks O
of O
treatment O
. O

Cushing B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
patients O
with O
poor B-Not_AE_Candidate
glycemic I-Not_AE_Candidate
control I-Not_AE_Candidate
( O
as O
defined O
by O
HbA B-NonOSE_AE
1 I-NonOSE_AE
c I-NonOSE_AE
values I-NonOSE_AE
> I-NonOSE_AE
8 I-NonOSE_AE
% I-NonOSE_AE
while O
receiving O
anti-diabetic O
therapy O
) O
may O
be O
at O
a O
higher O
risk O
of O
developing O
severe O
hyperglycemia B-NonOSE_AE
and O
associated O
complications O
, O
e.g. O
, O
ketoacidosis B-NonOSE_AE
. O

Because O
of O
this O
predictable O
adverse O
reaction O
, O
the O
glycemic O
status O
[ O
fasting O
plasma O
glucose O
( O
FPG O
) O
or O
hemoglobin O
A1c O
( O
HbA1c O
) O
] O
should O
be O
assessed O
prior O
to O
starting O
treatment O
with O
SIGNIFOR O
. O

In O
patients O
with O
uncontrolled B-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
intensive O
anti-diabetic O
therapy O
should O
be O
optimized O
prior O
to O
treatment O
with O
SIGNIFOR O
. O

Self-monitoring O
of O
blood O
glucose O
and/or O
FPG O
assessments O
should O
be O
done O
every O
week O
for O
the O
first O
two O
to O
three O
months O
and O
periodically O
thereafter O
, O
as O
clinically O
appropriate O
, O
as O
well O
as O
over O
the O
first O
two O
to O
four O
weeks O
after O
any O
dose O
increase O
. O

After O
treatment O
discontinuation O
, O
glycemic O
monitoring O
( O
e.g. O
, O
FPG O
or O
HbA1c O
) O
should O
be O
done O
according O
to O
clinical O
practice O
. O

Patients O
who O
were O
initiated O
on O
anti-diabetic O
therapy O
as O
a O
result O
of O
SIGNIFOR O
may O
require O
closer O
monitoring O
after O
discontinuation O
of O
SIGNIFOR O
, O
especially O
if O
the O
anti-diabetic O
therapy O
has O
a O
risk O
of O
causing O
hypoglycemia B-NonOSE_AE
. O

If O
hyperglycemia B-NonOSE_AE
develops O
in O
a O
patient O
treated O
with O
SIGNIFOR O
, O
the O
initiation O
or O
adjustment O
of O
anti-diabetic O
treatment O
per O
standard O
of O
care O
is O
recommended O
. O

The O
optimal O
treatment O
for O
the O
management O
of O
SIGNIFOR-induced O
hyperglycemia B-NonOSE_AE
is O
not O
known O
. O

If O
uncontrolled O
hyperglycemia B-NonOSE_AE
persists O
, O
despite O
appropriate O
medical O
management O
, O
the O
dose O
of O
SIGNIFOR O
should O
be O
reduced O
or O
discontinued O
. O

5.3 O
Bradycardia O
and O
QT O
Prolongation O
Bradycardia O
Bradycardia B-OSE_Labeled_AE
has O
been O
reported O
with O
the O
use O
of O
SIGNIFOR O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Patients O
with O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
and/or O
risk O
factors O
for O
bradycardia B-Not_AE_Candidate
, O
such O
as O
history O
of O
clinically O
significant O
bradycardia B-Not_AE_Candidate
, O
high-grade O
heart B-Not_AE_Candidate
block I-Not_AE_Candidate
, O
or O
concomitant O
use O
of O
drugs O
associated O
with O
bradycardia B-Not_AE_Candidate
, O
should O
be O
carefully O
monitored O
. O

Dose O
adjustments O
of O
beta-blockers O
, O
calcium O
channel O
blockers O
, O
or O
correction O
of O
electrolyte B-NonOSE_AE
disturbances I-NonOSE_AE
may O
be O
necessary O
. O

QT O
Prolongation O
SIGNIFOR O
is O
associated O
with O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
. O

In O
two O
thorough O
QT O
studies O
with O
SIGNIFOR O
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
occurred O
at O
therapeutic O
and O
supra-therapeutic O
doses O
. O

SIGNIFOR O
should O
be O
used O
with O
caution O
in O
patients O
who O
are O
at O
significant O
risk O
of O
developing O
prolongation B-NonOSE_AE
of I-NonOSE_AE
QTc I-NonOSE_AE
, O
such O
as O
those O
: O
* O
with O
congenital B-Not_AE_Candidate
long I-Not_AE_Candidate
QT I-Not_AE_Candidate
prolongation I-Not_AE_Candidate
. O

* O
with O
uncontrolled O
or O
significant O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
including O
recent B-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
unstable B-Not_AE_Candidate
angina I-Not_AE_Candidate
or O
clinically O
significant O
bradycardia B-Not_AE_Candidate
. O

* O
on O
anti-arrhythmic O
therapy O
or O
other O
substances O
that O
are O
known O
to O
lead O
to O
QT B-Not_AE_Candidate
prolongation I-Not_AE_Candidate
. O

* O
with O
hypokalemia B-Not_AE_Candidate
and/or O
hypomagnesemia B-Not_AE_Candidate
. O

A O
baseline O
ECG O
is O
recommended O
prior O
to O
initiating O
therapy O
with O
SIGNIFOR O
and O
monitoring O
for O
an O
effect O
on O
the O
QTc O
interval O
is O
advisable O
. O

Hypokalemia B-NonOSE_AE
and O
hypomagnesemia B-NonOSE_AE
must O
be O
corrected O
prior O
to O
SIGNIFOR O
administration O
and O
should O
be O
monitored O
periodically O
during O
therapy O
. O

5.4 O
Liver O
Test O
Elevations O
In O
the O
Phase O
III O
trial O
, O
5 O
% O
of O
patients O
had O
an O
ALT B-OSE_Labeled_AE
or O
AST O
level O
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
( O
ULN O
) O
. O

In O
the O
entire O
clinical O
development O
program O
of O
SIGNIFOR O
, O
there O
were O
4 O
cases O
of O
concurrent O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
( O
alanine O
aminotransferase O
) O
greater O
than O
3 O
x O
ULN O
and O
bilirubin B-OSE_Labeled_AE
greater I-OSE_Labeled_AE
than O
2 O
x O
ULN O
: O
one O
patient O
with O
Cushing O
's O
disease O
and O
three O
healthy O
volunteers O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

In O
these O
cases O
, O
total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
seen O
either O
concomitantly O
or O
preceding O
the O
transaminase B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
. O

Monitoring O
of O
liver O
tests O
should O
be O
done O
after O
1 O
to O
2 O
weeks O
on O
treatment O
, O
then O
monthly O
for O
3 O
months O
, O
and O
every O
6 O
months O
thereafter O
. O

If O
ALT O
is O
normal O
at O
baseline O
and O
elevations B-NonOSE_AE
of I-NonOSE_AE
ALT I-NonOSE_AE
of O
3-5 O
times O
the O
ULN O
are O
observed O
on O
treatment O
, O
repeat O
the O
test O
within O
a O
week O
or O
within O
48 O
hours O
if O
exceeding O
5 O
times O
ULN O
. O

If O
ALT B-NonOSE_AE
is I-NonOSE_AE
abnormal I-NonOSE_AE
at O
baseline O
and O
elevations B-NonOSE_AE
of I-NonOSE_AE
ALT I-NonOSE_AE
of O
3-5 O
times O
the O
baseline O
values O
are O
observed O
on O
treatment O
, O
repeat O
the O
test O
within O
a O
week O
or O
sooner O
if O
exceeding O
5 O
times O
ULN O
. O

Tests O
should O
be O
done O
in O
a O
laboratory O
that O
can O
provide O
same-day O
results O
. O

If O
the O
values O
are O
confirmed O
or O
rising O
, O
interrupt O
SIGNIFOR O
treatment O
and O
investigate O
for O
probable O
cause O
of O
the O
findings O
, O
which O
may O
or O
may O
not O
be O
SIGNIFOR-related O
. O

Serial O
measures O
of O
ALT O
, O
aspartate O
aminotransferase O
, O
alkaline O
phosphatase O
, O
and O
total O
bilirubin O
, O
should O
be O
done O
weekly O
, O
or O
more O
frequently O
, O
if O
any O
value O
exceeds O
5 O
times O
the O
baseline O
value O
in O
case O
of O
abnormal O
baselines O
or O
5 O
times O
the O
ULN O
in O
case O
of O
normal O
baselines O
. O

If O
resolution O
of O
abnormalities O
to O
normal O
or O
near O
normal O
occurs O
, O
resuming O
treatment O
with O
SIGNIFOR O
may O
be O
done O
cautiously O
, O
with O
close O
observation O
, O
and O
only O
if O
some O
other O
likely O
cause O
has O
been O
found O
. O

5.5 O
Cholelithiasis O
Cholelithiasis B-OSE_Labeled_AE
has O
been O
frequently O
reported O
in O
clinical O
studies O
with O
SIGNIFOR O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Ultrasonic O
examination O
of O
the O
gallbladder O
before O
, O
and O
at O
6- O
to O
12-month O
intervals O
during O
SIGNIFOR O
therapy O
is O
recommended O
. O

5.6 O
Monitoring O
for O
Deficiency O
of O
Pituitary O
Hormones O
As O
the O
pharmacological O
activity O
of O
SIGNIFOR O
mimics O
that O
of O
somatostatin O
, O
inhibition B-OSE_Labeled_AE
of I-OSE_Labeled_AE
pituitary I-OSE_Labeled_AE
hormones I-OSE_Labeled_AE
, O
other O
than O
ACTH O
, O
may O
occur O
. O

Monitoring O
of O
pituitary O
function O
( O
e.g. O
, O
TSH/free O
T4 O
, O
GH/IGF-1 O
) O
should O
occur O
prior O
to O
initiation O
of O
therapy O
with O
SIGNIFOR O
and O
periodically O
during O
treatment O
should O
be O
considered O
as O
clinically O
appropriate O
. O

Patients O
who O
have O
undergone O
transsphenoidal B-Not_AE_Candidate
surgery I-Not_AE_Candidate
and O
pituitary B-Not_AE_Candidate
irradiation I-Not_AE_Candidate
are O
particularly O
at O
increased O
risk O
for O
deficiency B-NonOSE_AE
of O
pituitary I-NonOSE_AE
hormones I-NonOSE_AE
. O

